AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
AngioDynamics's 15min chart triggers KDJ Death Cross and Bearish Marubozu signal.
ByAinvest
Tuesday, Oct 21, 2025 1:02 pm ET1min read
AngioDynamics's 15-minute chart has recently triggered a KDJ Death Cross and a Bearish Marubozu, which indicates a shift in momentum towards the downside. This suggests that the stock price may continue to decrease, as sellers currently dominate the market. The bearish momentum is expected to persist, indicating a negative trend in the company's financial performance.
AngioDynamics Inc. (ANGO) reported its first-quarter fiscal 2026 results, showing mixed financial performance. Net sales increased by 12.2% to $75.7 million, driven by a 26.1% growth in Med Tech revenue, led by Auryon, NanoKnife, and thrombus management products. Med Device revenue grew modestly by 2.3%. The company's gross margin improved by 90 basis points to 55.3% [1].Despite the revenue growth, AngioDynamics recorded a net loss of $10.9 million, a significant improvement from the prior year's loss of $12.8 million. The company continues to restructure its operations, with $2.3 million in charges recorded this quarter and a total of $25.6 million recorded to date. A settlement with BD (Becton, Dickinson) includes a one-time lump-sum payment of $2.5 million and ongoing minimum annual payments, with a contingent $3.0 million potentially due depending on the Federal Circuit appeal [1].
Technical indicators for AngioDynamics' stock have recently shown bearish signs. The 15-minute chart has triggered a KDJ Death Cross and a Bearish Marubozu, suggesting a shift in momentum towards the downside. This indicates that sellers currently dominate the market, and the stock price may continue to decrease. The bearish momentum is expected to persist, indicating a negative trend in the company's financial performance .
AngioDynamics has a $25.0 million revolving credit facility with $0 drawn as of August 31, 2025, providing liquidity optionality. However, management has flagged ongoing macroeconomic risks, supply-chain pressures, and inflation as potential challenges that could affect cash flow and margins [1].
The company is also defending approximately 219 Port Product Claims consolidated for pretrial proceedings, which could materially affect estimates if additional claims emerge or details change [1].
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet